在管理未先进和先进的全身性巨细胞瘤中,KIT向药物
Andreas Reiter1, Julien Rossignol2, Michael W Deininger3
1Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
The journal of allergy and clinical immunology. In practice
|November 4, 2025
概括
系统性巨细胞瘤 (SM) 是一种罕见的癌症. 诊断包括评估血液,骨髓和器官透,指导KIT针对高级和惰形式的向治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 罕见疾病 罕见疾病
背景情况:
- 系统性巨细胞瘤 (SM) 是一种罕见的血液性瘤.
- 基特D816V突变导致多达95%的MS病例.
- 乳腺癌分为不发达和发达的亚型,每个亚型都有不同的临床影响.
研究的目的:
- 讨论KIT D816V阳性SM的诊断和治疗.
- 为了突出高级SM (AdvSM) 和惰的SM (ISM) 患者的管理.
- 强调KIT向治疗在SM管理中的作用.
主要方法:
- 综合诊断工作,包括周围血液分析 (血液计数,血清三酶,KIT D816V VAF,体质突变).
- 骨髓 (BM) 评估巨细胞透,KIT D816V VAF,相关的血液瘤和细胞遗传学.
- 评估器官透和功能障碍,特别是在皮肤,骨/骨和内脏器官.
主要成果:
- 详细讨论了两个患者病例:一个是AdvSM,一个是ISM,两者都是KIT D816V阳性.
- 描绘了由巨细胞介导体症状和器官透引起的异质临床表现.
- 在接受治疗的患者中展示了KIT向疗法的应用.
结论:
- 精确诊断MS需要对临床和实验室参数进行彻底评估.
- 多方面的诊断方法对于有效的患者管理至关重要.
- 针对KIT的疗法是KIT D816V阳性SM患者的关键治疗方式.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
426
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
426


